Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

ClinicalTrials.gov ID: NCT00548925

Public ClinicalTrials.gov record NCT00548925. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 8, 2026, 12:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894 Versus Placebo in Subjects With Diabetic Neuropathic Pain

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and efficacy of a 6 mg twice a day dose of an investigational product in subjects with diabetic neuropathy

Study identification

NCT ID
NCT00548925
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Enrollment
124 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2007
Primary completion
Nov 30, 2008
Completion
Nov 30, 2008
Last update posted
Jan 20, 2013

2007 – 2008

United States locations

U.S. sites
12
U.S. states
8
U.S. cities
11
Facility City State ZIP Site status
Site Reference ID/Investigator# 6614 Spring Valley California 91978
Site Reference ID/Investigator# 6617 Walnut Creek California 94598
Site Reference ID/Investigator# 6356 Hollywood Florida 33021
Site Reference ID/Investigator# 6615 Tampa Florida 33603
Site Reference ID/Investigator# 6358 Wellington Florida 33414
Site Reference ID/Investigator# 6609 St Louis Missouri 63141
Site Reference ID/Investigator# 7229 New Hyde Park New York 11042
Site Reference ID/Investigator# 6618 Charlotte North Carolina 28211
Site Reference ID/Investigator# 6607 Oklahoma City Oklahoma 73103
Site Reference ID/Investigator# 6575 Allentown Pennsylvania 18103
Site Reference ID/Investigator# 8179 San Antonio Texas 78229-4801
Site Reference ID/Investigator# 6616 San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00548925, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 20, 2013 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00548925 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →